{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:16:24Z","timestamp":1790626584537,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>During acute-phase response (APR), there is a dramatic increase in serum amyloid A (SAA) in plasma high density lipoproteins (HDL). Elevated SAA leads to reactive AA amyloidosis in animals and humans. Herein, we employed apolipoprotein A-II (ApoA-II) deficient <jats:italic>(Apoa2<\/jats:italic><jats:sup>\n                  <jats:italic>\u2212\/\u2212<\/jats:italic>\n                <\/jats:sup>) and transgenic (<jats:italic>Apoa2<\/jats:italic>Tg) mice to investigate the potential roles of ApoA-II in lipoprotein particle formation and progression of AA amyloidosis during APR. AA amyloid deposition was suppressed in <jats:italic>Apoa2<\/jats:italic><jats:sup>\n                  <jats:italic>\u2212\/\u2212<\/jats:italic>\n                <\/jats:sup> mice compared with wild type (WT) mice. During APR, <jats:italic>Apoa2<\/jats:italic><jats:sup>\n                  <jats:italic>\u2212\/\u2212<\/jats:italic>\n                <\/jats:sup> mice exhibited significant suppression of serum SAA levels and hepatic <jats:italic>Saa1<\/jats:italic> and <jats:italic>Saa2<\/jats:italic> mRNA levels. Pathological investigation showed <jats:italic>Apoa2<\/jats:italic><jats:sup>\n                  <jats:italic>\u2212\/\u2212<\/jats:italic>\n                <\/jats:sup> mice had less tissue damage and less inflammatory cell infiltration during APR. Total lipoproteins were markedly decreased in <jats:italic>Apoa2<\/jats:italic><jats:sup>\n                  <jats:italic>\u2212\/\u2212<\/jats:italic>\n                <\/jats:sup> mice, while the ratio of HDL to low density lipoprotein (LDL) was also decreased. Both WT and <jats:italic>Apoa2<\/jats:italic><jats:sup>\n                  <jats:italic>\u2212\/\u2212<\/jats:italic>\n                <\/jats:sup> mice showed increases in LDL and very large HDL during APR. SAA was distributed more widely in lipoprotein particles ranging from chylomicrons to very small HDL in <jats:italic>Apoa2<\/jats:italic><jats:sup>\n                  <jats:italic>\u2212\/\u2212<\/jats:italic>\n                <\/jats:sup> mice. Our observations uncovered the critical roles of ApoA-II in inflammation, serum lipoprotein stability and AA amyloidosis morbidity, and prompt consideration of therapies for AA and other amyloidoses, whose precursor proteins are associated with circulating HDL particles.<\/jats:p>","DOI":"10.1038\/s41598-018-23755-y","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T22:45:29Z","timestamp":1522363529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Apolipoprotein A-II induces acute-phase response associated AA amyloidosis in mice through conformational changes of plasma lipoprotein structure"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-2434","authenticated-orcid":false,"given":"Mu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Miyahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinko","family":"Sawashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"key":"23755_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini, G. & Bellotti, V. Molecular mechanisms of amyloidosis. N Engl J Med 349, 583\u2013596 (2003).","journal-title":"N Engl J Med"},{"key":"23755_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3109\/13506120209114823","volume":"9","author":"P Westermark","year":"2002","unstructured":"Westermark, P. et al. Amyloid fibril protein nomenclature\u20132002. Amyloid 9, 197\u2013200 (2002).","journal-title":"Amyloid"},{"key":"23755_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","volume":"23","author":"JD Sipe","year":"2016","unstructured":"Sipe, J. D. et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 23, 209\u2013213 (2016).","journal-title":"Amyloid"},{"key":"23755_CR4","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann, H. J. et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 356, 2361\u201371 (2007).","journal-title":"N Engl J Med."},{"key":"23755_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1177\/030098587100800402","volume":"8","author":"W Jakob","year":"1971","unstructured":"Jakob, W. Spontaneous amyloidosis of mammals. Vet Pathol 8, 292\u2013306 (1971).","journal-title":"Vet Pathol"},{"key":"23755_CR6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/03079459808419367","volume":"27","author":"WJ Landman","year":"1998","unstructured":"Landman, W. J. et al. Avian amyloidosis. Avian Pathol 27, 437\u2013449 (1998).","journal-title":"Avian Pathol"},{"key":"23755_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0950-3579(05)80115-3","volume":"8","author":"G Marhaug","year":"1994","unstructured":"Marhaug, G. & Dowton, S. B. Serum amyloid A: an acute phase apolipoprotein and precursor of AA amyloid. Baillieres Clin. Rheumatol 8, 553\u2013573 (1994).","journal-title":"Baillieres Clin. Rheumatol"},{"key":"23755_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/13506129.2011.654294","volume":"19","author":"R Kisilevsky","year":"2012","unstructured":"Kisilevsky, R. & Manley, P. N. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid 19, 5\u201314 (2012).","journal-title":"Amyloid"},{"key":"23755_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/ard.59.8.577","volume":"59","author":"BP Hazenberg","year":"2000","unstructured":"Hazenberg, B. P. & van Rijswijk, M. H. Where has secondary amyloid gone? Ann Rheum Dis. 59, 577\u2013579 (2000).","journal-title":"Ann Rheum Dis."},{"key":"23755_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2174\/157339707781387581","volume":"3","author":"T Nakamura","year":"2007","unstructured":"Nakamura, T. Amyloid A amyloidosis secondary to rheumatoid arthritis: uncommon yet important complication. Curr Rheumatol Rev 3, 231\u2013241 (2007).","journal-title":"Curr Rheumatol Rev"},{"key":"23755_CR11","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1073\/pnas.74.9.4025","volume":"74","author":"EP Benditt","year":"1977","unstructured":"Benditt, E. P. & Eriksen, N. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc. Natl. Acad. Sci. USA 74, 4025\u20134028 (1977).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"23755_CR12","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/j.1365-3083.1977.tb00379.x","volume":"6","author":"B Skogen","year":"1977","unstructured":"Skogen, B. et al. A high molecular weight serum protein is the carrier for amyloid-related protein SAA. Scand. J. Immunol 6, 1363\u20131368 (1977).","journal-title":"Scand. J. Immunol"},{"key":"23755_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1084\/jem.159.2.641","volume":"159","author":"JS Hoffman","year":"1984","unstructured":"Hoffman, J. S. et al. Murine tissue amyloid protein AA. NH2-terminal sequence identity with only one of two serum amyloid protein (ApoSAA) gene products. J Exp Med 159, 641\u2013646 (1984).","journal-title":"J Exp Med"},{"key":"23755_CR14","doi-asserted-by":"publisher","first-page":"8492","DOI":"10.1074\/jbc.M109.007526","volume":"285","author":"IN Baranova","year":"2010","unstructured":"Baranova, I. N. et al. CD36 is a novel serum amyloid A (SAA) receptor mediating SAA binding and SAA-induced signaling in human and rodent cells. J Biol Chem. 285, 8492\u20138506 (2010).","journal-title":"J Biol Chem."},{"key":"23755_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4049\/jimmunol.181.1.22","volume":"181","author":"N Cheng","year":"2008","unstructured":"Cheng, N. et al. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 181, 22\u201326 (2008).","journal-title":"J Immunol"},{"key":"23755_CR16","doi-asserted-by":"crossref","first-page":"10510","DOI":"10.1016\/S0021-9258(18)34047-X","volume":"257","author":"JS Hoffman","year":"1982","unstructured":"Hoffman, J. S. & Benditt, E. P. Changes in high density lipoprotein content following endotoxin administration in the mouse: formation of serum amyloid protein-rich subfractions. J Biol Chem 257, 10510\u201310517 (1982).","journal-title":"J Biol Chem"},{"key":"23755_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1006\/bbrc.1994.1229","volume":"199","author":"K Ganowiak.","year":"1994","unstructured":"Ganowiak., K. et al. Fibrils from synthetic amyloid-related peptides enhance development of experimental AA-amyloidosis in mice. Biochem Biophys Res Commun 199, 306\u201312 (1994).","journal-title":"Biochem Biophys Res Commun"},{"key":"23755_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3109\/13506129.2013.783474","volume":"20","author":"T Murakami","year":"2013","unstructured":"Murakami, T. et al. Experimental induction and oral transmission of avian AA amyloidosis in vaccinated white hens. Amyloid 20, 80\u20135 (2013).","journal-title":"Amyloid"},{"key":"23755_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/13506120802005882","volume":"15","author":"N Horiuchi","year":"2008","unstructured":"Horiuchi, N. et al. Experimental induction of amyloidosis by bovine amyloid fibrils in sore hock rabbits. Amyloid 15, 84\u201388 (2008).","journal-title":"Amyloid"},{"key":"23755_CR20","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.2741\/1887","volume":"11","author":"JC Escola-Gil","year":"2006","unstructured":"Escola-Gil, J. C. et al. Antiatherogenic role of high-density lipoproteins: insights from genetically engineered-mice. Front Biosci 11, 1328\u20131348 (2006).","journal-title":"Front Biosci"},{"key":"23755_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2010.12.003","volume":"130","author":"O David","year":"2011","unstructured":"David, O. et al. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. Pharmacol Ther 130, 83\u201391 (2011).","journal-title":"Pharmacol Ther"},{"key":"23755_CR22","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0022-2275(20)31499-1","volume":"42","author":"F Blanco-Vaca.","year":"2001","unstructured":"Blanco-Vaca., F. et al. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J. Lipid Res 42, 1727\u20131739 (2001).","journal-title":"J. Lipid Res"},{"key":"23755_CR23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0022-2275(20)31165-2","volume":"42","author":"CH Catherine","year":"2001","unstructured":"Catherine, C. H. et al. In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions. J Lipid Res 42, 563\u2013570 (2001).","journal-title":"J Lipid Res"},{"key":"23755_CR24","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1172\/JCI117614","volume":"94","author":"Shaobin Zhong.","year":"1994","unstructured":"Shaobin Zhong. et al. Human ApoA-II Inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size Induced by hypertriglyceridemia and cholesteryl ester transfer Protein in transgenic mice. J Clin Invest 94, 2457\u20132467 (1994).","journal-title":"J Clin Invest"},{"key":"23755_CR25","doi-asserted-by":"crossref","first-page":"20676","DOI":"10.1016\/S0021-9258(20)80777-7","volume":"268","author":"CC Hedrick","year":"1993","unstructured":"Hedrick, C. C. et al. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem 268, 20676\u201320682 (1993).","journal-title":"J Biol Chem"},{"key":"23755_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0014-5793(86)80732-3","volume":"203","author":"T Yonezu","year":"1986","unstructured":"Yonezu, T. et al. High homology is present in the primary structures between murine senile amyloid protein (ASSAM) and human apolipoprotein A-II. FEBS Lett 203, 149\u201352 (1986).","journal-title":"FEBS Lett"},{"key":"23755_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1042\/bj2790427","volume":"279","author":"K Higuchi.","year":"1991","unstructured":"Higuchi., K. et al. Polymorphism of apolipoprotein A-II (apoA-II) among inbred strains of mice. Relationship between the molecular type of apoA-II and mouse senile amyloidosis. Biochem J 279, 427\u201333 (1991).","journal-title":"Biochem J"},{"key":"23755_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2353\/ajpath.2007.060576","volume":"171","author":"J Yan","year":"2007","unstructured":"Yan, J. et al. Cross-seeding and crosscompetition in mouse apolipoprotein A-II amyloid fibrils and protein A amyloid fibrils. Am J Pathol 171, 172\u201380 (2007).","journal-title":"Am J Pathol"},{"key":"23755_CR29","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1194\/jlr.M013235","volume":"52","author":"Y Wang","year":"2011","unstructured":"Wang, Y. et al. ApoA-I deficiency in mice is associated with redistribution of apoA-II and aggravated AApoAII amyloidosis. J Lipid Res 52, 1461\u20131470 (2011).","journal-title":"J Lipid Res"},{"key":"23755_CR30","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1073\/pnas.77.11.6860","volume":"77","author":"N Eriksen","year":"1980","unstructured":"Eriksen, N. & Benditt, E. P. Isolation and characterization of the amyloid-related apoprotein (SAA) from human high density lipoprotein. Proc Natl Acad Sci USA 77, 6860\u20136864 (1980).","journal-title":"Proc Natl Acad Sci USA"},{"key":"23755_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0021-9150(00)00437-8","volume":"154","author":"D Ashby","year":"2001","unstructured":"Ashby, D. et al. Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression. Atherosclerosis. 154, 113\u2013121 (2001).","journal-title":"Atherosclerosis."},{"key":"23755_CR32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/labinvest.3700559","volume":"87","author":"Fengxia Ge.","year":"2007","unstructured":"Fengxia Ge. et al. Amyloidosis in transgenic mice expressing murine amyloidogenic apolipoprotein A-II (Apoa2c). Laboratory Investigation 87, 633\u2013643 (2007).","journal-title":"Laboratory Investigation"},{"key":"23755_CR33","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1194\/jlr.M200405-JLR200","volume":"44","author":"M Umezawa","year":"2003","unstructured":"Umezawa, M. et al. Dietary fat modulation of apoA-II metabolism and prevention of senile amyloidosis in the senescence- accelerated mouse. J. Lipid Res 44, 762\u2013769 (2003).","journal-title":"J. Lipid Res"},{"key":"23755_CR34","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1172\/JCI119554","volume":"100","author":"LW Castellani","year":"1997","unstructured":"Castellani, L. W. et al. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 100, 464\u2013474 (1997).","journal-title":"J Clin Invest"},{"key":"23755_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1753425908099171","volume":"14","author":"PA Thompson","year":"2008","unstructured":"Thompson, P. A. et al. Apolipoprotein A-II augments monocyte responses to LPS by suppressing the inhibitory activity of LPS-binding protein. Innate Immun 14, 365\u2013374 (2008).","journal-title":"Innate Immun"},{"key":"23755_CR36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4093\/dmj.2016.40.3.222","volume":"40","author":"F Koohdani","year":"2016","unstructured":"Koohdani, F. et al. APOA2 -265T\/C polymorphism is associated with increased inflammatory responses in patients with type 2 diabetes mellitus. Diabetes Metab J 40, 222\u2013229 (2016).","journal-title":"Diabetes Metab J"},{"key":"23755_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020712-163913","volume":"10","author":"GT Westermark","year":"2015","unstructured":"Westermark, G. T. et al. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol 10, 321\u2013344 (2015).","journal-title":"Annu Rev Pathol"},{"key":"23755_CR38","doi-asserted-by":"publisher","first-page":"e79104","DOI":"10.1371\/journal.pone.0079104","volume":"8","author":"K Lundmark","year":"2013","unstructured":"Lundmark, K. et al. Depletion of spleen macrophages delays AA amyloid development: a study performed in the rapid mouse model of AA amyloidosis. PLoS One 8, e79104 (2013).","journal-title":"PLoS One"},{"key":"23755_CR39","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.ajpath.2012.12.035","volume":"182","author":"J Sponarova","year":"2013","unstructured":"Sponarova, J. et al. Efficient amyloid A clearance in the absence of immunoglobulins and complement factors. Am J Pathol 182, 1297\u2013307 (2013).","journal-title":"Am J Pathol"},{"key":"23755_CR40","doi-asserted-by":"publisher","first-page":"16115","DOI":"10.1073\/pnas.1306621110","volume":"110","author":"JP Simons","year":"2013","unstructured":"Simons, J. P. et al. Pathogenetic mechanisms of amyloid A amyloidosis. Proc Natl Acad Sci USA 110, 16115\u201316120 (2013).","journal-title":"Proc Natl Acad Sci USA"},{"key":"23755_CR41","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0002-9440(10)65378-3","volume":"154","author":"A Solomon","year":"1999","unstructured":"Solomon, A. et al. Transgenic mouse model of AA amyloidosis. Am J Pathol 154, 1267\u20131272 (1999).","journal-title":"Am J Pathol"},{"key":"23755_CR42","doi-asserted-by":"publisher","first-page":"e0172402","DOI":"10.1371\/journal.pone.0172402","volume":"12","author":"Lin Li.","year":"2017","unstructured":"Lin Li. et al. Caloric restriction reduces the systemic progression of mouse AApoAII amyloidosis. PLoS One 12, e0172402 (2017).","journal-title":"PLoS One"},{"key":"23755_CR43","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1194\/jlr.R300019-JLR200","volume":"45","author":"W Khovidhunkit","year":"2004","unstructured":"Khovidhunkit, W. et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res 45, 1169\u20131196 (2004).","journal-title":"J. Lipid Res"},{"key":"23755_CR44","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.bbalip.2016.04.013","volume":"1861","author":"M Trieb","year":"2016","unstructured":"Trieb, M. et al. Liver disease alters high-density lipoprotein composition, metabolism and function. Biochim Biophys Acta 1861, 630\u2013638 (2016).","journal-title":"Biochim Biophys Acta"},{"key":"23755_CR45","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1128\/iai.60.2.596-601.1992","volume":"60","author":"K Emancipator","year":"1992","unstructured":"Emancipator, K. et al. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 60, 596\u2013601 (1992).","journal-title":"Infect Immun"},{"key":"23755_CR46","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1128\/iai.61.12.5140-5146.1993","volume":"61","author":"WA Flegel","year":"1993","unstructured":"Flegel, W. A. et al. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 61, 5140\u20135146 (1993).","journal-title":"Infect Immun"},{"key":"23755_CR47","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/abbs\/36.6.419","volume":"36","author":"J Ma","year":"2004","unstructured":"Ma, J. et al. Role of apolipoprotein A-I in protecting against endotoxin toxicity. Acta Biochim Biophys Sin 36, 419\u2013424 (2004).","journal-title":"Acta Biochim Biophys Sin"},{"key":"23755_CR48","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/0026-0495(88)90120-5","volume":"37","author":"K Sammalkorpi","year":"1988","unstructured":"Sammalkorpi, K. et al. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 37, 859\u2013865 (1988).","journal-title":"Metabolism"},{"key":"23755_CR49","first-page":"1045","volume":"74","author":"C Grunfeld","year":"1992","unstructured":"Grunfeld, C. et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab 74, 1045\u20131052 (1992).","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"23755_CR50","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/S0022-2275(20)35355-4","volume":"34","author":"KR Feingold","year":"1993","unstructured":"Feingold, K. R. et al. Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. J. Lipid Res 34, 2147\u20132158 (1993).","journal-title":"J. Lipid Res"},{"key":"23755_CR51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0022-2275(20)38390-5","volume":"30","author":"VG Cabana","year":"1989","unstructured":"Cabana, V. G. et al. Effects of the acute phase response on the concentration and density distributionnof plasma lipids and apolipoproteins. J. Lipid Res 30, 39\u201349 (1989).","journal-title":"J. Lipid Res"},{"key":"23755_CR52","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0022-2275(20)34244-9","volume":"26","author":"PM Clifton","year":"1985","unstructured":"Clifton, P. M. et al. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J. Lipid Res 26, 1389\u20131398 (1985).","journal-title":"J. Lipid Res"},{"key":"23755_CR53","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0022-2275(20)32143-X","volume":"40","author":"H Hosoai","year":"1999","unstructured":"Hosoai, H. et al. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J. Lipid Res 40, 648\u2013653 (1999).","journal-title":"J. Lipid Res"},{"key":"23755_CR54","doi-asserted-by":"publisher","first-page":"14788","DOI":"10.1073\/pnas.93.25.14788","volume":"93","author":"W Weng","year":"1996","unstructured":"Weng, W. & Breslow, J. L. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc. Natl. Acad. Sci. USA 93, 14788\u201314794 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"23755_CR55","doi-asserted-by":"crossref","first-page":"16380","DOI":"10.1016\/S0021-9258(17)46234-X","volume":"265","author":"MH Doolittle","year":"1990","unstructured":"Doolittle, M. H. et al. A polymorphism affecting apolipoprotein A-II transla- tional efficiency determines high density lipoprotein size and composition. J. Biol. Chem 265, 16380\u201316388 (1990).","journal-title":"J. Biol. Chem"},{"key":"23755_CR56","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1096\/fj.08-117150","volume":"22","author":"AM Scanu","year":"2008","unstructured":"Scanu, A. M. & Edelstein, C. HDL: bridging past and present with a look at the future. FASEB J 22, 4044\u20134054 (2008).","journal-title":"FASEB J"},{"key":"23755_CR57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.biochi.2013.08.027","volume":"96","author":"SF Ma\u00efga","year":"2014","unstructured":"Ma\u00efga, S. F. et al. Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes. Biochimie 96, 56\u201366 (2014).","journal-title":"Biochimie"},{"key":"23755_CR58","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1021\/bi300555d","volume":"51","author":"X Gao","year":"2012","unstructured":"Gao, X. et al. Role of apolipoprotein A-II in the structure and remodeling of human high-density lipoprotein (HDL): protein conformational ensemble on HDL. Biochemistry 51, 4633\u20134641 (2012).","journal-title":"Biochemistry"},{"key":"23755_CR59","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/1873-3468.12116","volume":"590","author":"NM Frame","year":"2016","unstructured":"Frame, N. M. & Gursky, O. Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks. FEBS Lett 590, 866\u2013879 (2016).","journal-title":"FEBS Lett"},{"key":"23755_CR60","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/ATVBAHA.109.190264","volume":"29","author":"T Koike","year":"2009","unstructured":"Koike, T. et al. Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol 29, 2047\u20132053 (2009).","journal-title":"Arterioscler. Thromb. Vasc. Biol"},{"key":"23755_CR61","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/10.3.355","volume":"10","author":"H Puchtler","year":"1962","unstructured":"Puchtler, H. et al. On the binding of Congo red by amyloid. J. Histochem Cytochem 10, 355\u2013364 (1962).","journal-title":"J. Histochem Cytochem"},{"key":"23755_CR62","first-page":"231","volume":"48","author":"K Higuchi","year":"1983","unstructured":"Higuchi, K. et al. Systemic senile amyloid in senescence-accelerated mice: a unique fibril protein demonstrated in tissues from various organs by the unlabeled immunoperoxidase method. Lab Invest 48, 231\u2013240 (1983).","journal-title":"Lab Invest"},{"key":"23755_CR63","doi-asserted-by":"publisher","first-page":"33164","DOI":"10.1074\/jbc.M111570200","volume":"277","author":"Y Xing","year":"2002","unstructured":"Xing, Y. et al. Induction of protein conformational change in mouse senile amyloidosis. J Biol Chem 277, 33164\u201333169 (2002).","journal-title":"J Biol Chem"},{"key":"23755_CR64","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1073\/pnas.1416363112","volume":"112","author":"J Sawashita","year":"2015","unstructured":"Sawashita, J. et al. C-terminal sequence of amyloid- resistant type F apolipoprotein A-II inhibits amyloid fibril formation of apolipoprotein A-II in mice. Proc Natl Acad Sci USA 112, 836\u2013845 (2015).","journal-title":"Proc Natl Acad Sci USA"},{"key":"23755_CR65","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0002-9440(10)65234-0","volume":"155","author":"T Chiba","year":"1999","unstructured":"Chiba, T. et al. Mouse senile amyloid deposition is suppressed by adenovirus-mediated overexpression of amyloid-resistant apolipoprotein A-II. Am J Pathol 155, 1319\u20131326 (1999).","journal-title":"Am J Pathol"},{"key":"23755_CR66","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0047-6374(84)90103-9","volume":"26","author":"K Higuchi","year":"1984","unstructured":"Higuchi, K. et al. Age-related changes of serum apoprotein SASSAM, apoprotein A-I and low-density lipoprotein levels in senescence accelerated mouse (SAM). Mech Ageing Dev 26, 311\u201326 (1984).","journal-title":"Mech Ageing Dev"},{"key":"23755_CR67","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1161\/01.ATV.0000155017.60171.88","volume":"25","author":"M Okazaki","year":"2005","unstructured":"Okazaki, M. et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler. Thromb. Vasc. Biol 25, 578\u2013584 (2005).","journal-title":"Arterioscler. Thromb. Vasc. Biol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23755-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23755-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23755-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T04:01:49Z","timestamp":1671595309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23755-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["23755"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-23755-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,4]]},"assertion":[{"value":"2 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5620"}}